期刊
IMMUNOTHERAPY
卷 2, 期 5, 页码 637-650出版社
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.10.52
关键词
A771726; BK polyomavirus; cytomegalovirus disease-modifying antirheumatic drug; FK778; immunomodulation; pyrimidine synthesis; rheumatoid arthritis
类别
Leflunomide, an inhibitor of the dihydroorotase dehydrogenase and thereby pyrimidine synthesis, was introduced and licensed for the treatment of rheumatoid arthritis in 1998. In the following years, its antiviral properties were discovered and the drug was used in solid organ transplantation for polyomavirus type BK or cytomegalovirus infection. Owing to its long half-life and weak interaction with the cytochrome system, special considerations apply in the use of this drug. This article summarizes the clinical experience with leflunomide in rheumatology and in the evolving field of transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据